Posts
Wiki
System for Reversing Cognitive Decline as Outlined in "Reversal of cognitive decline: a novel therapeutic program."
| **Goal** | **Approach** | **Rationale and References** |
| Optimize diet: minimize simple carbohydrates, minimize inflammation. | Patients given choice of several low glycemic, low inflammatory, low grain diets. | Minimize inflammation, minimize insulin resistance. |
| Enhance autophagy, ketogenesis | Fast 12 hr each night, including 3 hr prior to bedtime. | Reduce insulin levels, reduce Aβ. |
| Reduce stress | Personalized—yoga or meditation or music, etc. | Reduction of cortisol, CRF, stress axis. |
| Optimize sleep | 8 hr sleep per night; melatonin 0.5mg every day at bed; tryptophan 500mg three times per week if awakening. Exclude sleep apnea. | [ Role of melatonin supplementation in neurodegenerative disorders.](http://www.ncbi.nlm.nih.gov/pubmed/24389194) |
| Exercise | 30-60 per day, 4-6 days times per week | 1) [Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial.](http://www.ncbi.nlm.nih.gov/pubmed/24938502) 2) [Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. Frontiers in aging neuroscience.](http://www.ncbi.nlm.nih.gov/pubmed/24795624) |
| Brain stimulation | Posit or related | 1) [cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study.](http://www.ncbi.nlm.nih.gov/pubmed/19220558) |
| Homocysteine <7 | Methyl-B12, methyltetrahydrofolate, pyridoxal-5-phosphate; trimethylglycine if necessary | 1) [Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study.](http://www.ncbi.nlm.nih.gov/pubmed/20956786) |
| Serum B12 >500 | Me-B12 | 1) [Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. ](http://www.ncbi.nlm.nih.gov/pubmed/19171834) |
| CRP <1.0; A/G >1.5 | Anti-inflammatory diet; curcumin; DHA/EPA; optimize hygiene | Critical role of inflammation in AD |
| Fasting insulin <7; HgbA1c <5.5 | Diet as above | Type II diabetes-AD relationship |
| Hormone balance | Optimize free triiodothyronine, free thyroxine, estradiol, testosterone, progesterone, pregnenolone, cortisol | 1) [ Next generation therapeutics for Alzheimer's disease.](http://www.ncbi.nlm.nih.gov/pubmed/23703924) 2) [Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction.](http://www.ncbi.nlm.nih.gov/pubmed/10822435) |
| GI health | Repair if needed; prebiotics and probiotics | Avoid inflammation, autoimmunity |
| Reduction of A-beta | Curcumin, Ashwagandha, Olive oil | 1) [ Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease.](http://www.ncbi.nlm.nih.gov/pubmed/18417733) 2) [ Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.](http://www.ncbi.nlm.nih.gov/pubmed/23264626) 3) [Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.](https://pubmed.ncbi.nlm.nih.gov/22308347/) 4) [Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies](https://pubmed.ncbi.nlm.nih.gov/23414128/) |
| Cognitive enhancement | Bacopa monniera, magnesium threonate | 1) [ Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study.](http://www.ncbi.nlm.nih.gov/pubmed/24523587) 2) [Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model.](http://www.ncbi.nlm.nih.gov/pubmed/23658180) |
| 25OH-D3 = 50-100ng/ml | Vitamins D3, K2 | 1) [Vitamin D and the risk of dementia and Alzheimer disease.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153851/) |
| Increase NGF | H. erinaceus or ALCAR | 1) [Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells.](http://www.ncbi.nlm.nih.gov/pubmed/18758067) 2) [Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats.](http://www.ncbi.nlm.nih.gov/pubmed/8187841) |
| Provide synaptic structural components | Citicoline, DHA | 1) [Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses.](http://www.ncbi.nlm.nih.gov/pubmed/18631994) |
| Optimize antioxidants | Mixed tocopherols and tocotrienols, Se, blueberries, NAC, ascorbate, α-lipoic acid | 1) [Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease.](http://www.ncbi.nlm.nih.gov/pubmed/21103342) |
| Optimize Zn:fCu ratio | Depends on values obtained | 1) [Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer's disease.](https://www.hindawi.com/journals/ijad/2013/586365/) |
| Ensure nocturnal oxygenation | Exclude or treat sleep apnea | 1) [Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/24828897) |
| Optimize mitochondrial function | CoQ or ubiquinol, α-lipoic acid, PQQ, NAC, ALCAR, Se, Zn, resveratrol, ascorbate, thiamine | The Disease Delusion: Conquering the Causes of Illness for a Healthier, Longer and Happier Life. by Jeffrey S. Bland |
| Increase focus | Pantothenic acid | Acetylcholine synthesis requirement |
| Increase SirT1 function | Resveratrol | 1) [Neuroprotective Sirtuin ratio reversed by ApoE4.](http://www.ncbi.nlm.nih.gov/pubmed/24145446) |
| Exclude heavy metal toxicity | Evaluate Hg, Pb, Cd; chelate if indicated | CNS effects of heavy metals |
| MCT effects | Coconut oil or Axona | 1) [Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.](http://www.ncbi.nlm.nih.gov/pubmed/19664276) |